Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC

被引：0
|
作者：
Navani, V. [1 ]
Lemelin, A. [1 ]
Powles, T. B. [2 ]
Liow, E. C. H. [3 ]
Wong, S. S. L. [4 ]
Meza, L. A. [5 ]
Ebrahimi, H. [5 ]
Saliby, R. M. [6 ]
Saad, E. [6 ]
Yuasa, T. [7 ]
Wood, L. A. [8 ]
Kollmannsberger, C. K. [9 ]
Graham, J. [10 ]
North, S. [11 ]
Basappa, N. S. [11 ]
Donskov, F. [12 ]
Suarez Rodriguez, C. [13 ]
Lalani, A-K. [14 ]
Choueiri, T. K. [6 ]
Heng, D. Y. C. [1 ]
机构：
[1] Tom Baker Canc Clin, Med Oncol Dept, Calgary, AB, Canada
[2] Barts Hlth NHS Trust, Oncol Dept, St Bartholomews Hosp, London, England
[3] Monash Hlth, Med Oncol, Monash Med Ctr, Clayton, Vic, Australia
[4] Western Hlth, Med Affairs Dept, Sunshine Hosp, St Albans, Vic, Australia
[5] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA
[6] Dana Farber Canc Inst, Med Oncol Dept, Boston, MA USA
[7] JFCR, Urol, Canc Inst Hosp, Koto Ku, Tokyo, Japan
[8] Dalhousie Univ, Div Med Oncol, Dept Med, Halifax, NS, Canada
[9] BC Canc Agcy Vancouver, Med Oncol Dept, Vancouver, BC, Canada
[10] Univ Manitoba, Med Oncol Dept, Fac Med Internal Med, Winnipeg, MB, Canada
[11] Univ Alberta, Med Oncol Dept, Cross Canc Inst, Edmonton, AB, Canada
[12] Aarhus Univ Hosp, Oncol Dept, Aarhus, Denmark
[13] Vall dHebron Univ Hosp, Oncol Dept, Barcelona, Spain
[14] Hamilton Hlth Sci, Genitourinary Oncol Dept, JCC Juravinski Canc Ctr, Med Oncol Div, Hamilton, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1893P
引用
收藏
页码：S1018 / S1019
页数：2
相关论文
共 50 条
  • [21] Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Takemura, Kosuke
    Graham, Jeffrey
    Maj, David
    Zarba, Martin
    Wells, Connor
    Chehade, Razane El Hajj
    Eid, Marc
    Saad, Eddy
    Saliby, Renee Maria
    Lee, Jae Lyun
    Donskov, Frede
    Beuselinck, Benoit
    Jude, Evon
    McKay, Rana R.
    Basappa, Naveen S.
    Pal, Sumanta Kumar
    Porta, Camillo
    Agarwal, Neeraj
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [22] Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment
    Chen, Yan
    Du, Ella X.
    Sundar, Manasvi
    Betts, Keith A.
    Yin, Xin
    Eiffert, Samantha
    Beauchamp, Karen
    Delgado, Andrew
    Rosenblatt, Lisa
    PHARMACOECONOMICS-OPEN, 2025, 9 (01) : 125 - 136
  • [23] Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium
    Takemura, Kosuke
    Navani, Vishal
    Ernst, Matthew S. S.
    Wells, J. Connor
    Meza, Luis
    Pal, Sumanta K. K.
    Lee, Jae-Lyun
    Li, Haoran
    Agarwal, Neeraj
    Alva, Ajjai S. S.
    Hansen, Aaron R. R.
    Basappa, Naveen S. S.
    Szabados, Bernadett
    Powles, Thomas
    Tran, Ben
    Hocking, Christopher M. M.
    Beuselinck, Benoit
    Yuasa, Takeshi
    Choueiri, Toni K. K.
    Heng, Daniel Y. C.
    JOURNAL OF UROLOGY, 2023, 209 (04): : 701 - 709
  • [24] Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Takemura, Kosuke
    Lemelin, Audreylie
    Ernst, Matthew S.
    Wells, J. Connor
    Saliby, Renee Maria
    El Zarif, Talal
    Labaki, Chris
    Basappa, Naveen S.
    Szabados, Bernadett
    Powles, Thomas
    Davis, Ian D.
    Wood, Lori A.
    Lalani, Aly-Khan A.
    Mckay, Rana R.
    Lee, Jae-Lyun
    Meza, Luis
    Pal, Sumanta K.
    Donskov, Frede
    Yuasa, Takeshi
    Beuselinck, Benoit
    Gebrael, Georges
    Agarwal, Neeraj
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN UROLOGY, 2024, 86 (06) : 488 - 492
  • [25] Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.
    Gupta, Mehul
    Wells, Connor
    Regan, Meredith M.
    Xie, Wanling
    Navani, Vishal
    Saliby, Renee Maria
    Basappa, Naveen S.
    Donskov, Frede
    Yuasa, Takeshi
    Takemura, Kosuke null
    Kollmannsberger, Christian K.
    Crumbaker, Megan
    Lalani, Aly-Khan A.
    Powles, Thomas
    Pal, Sumanta Kumar
    Mckay, Rana R.
    Lee, Jae-Lyun
    Kanesvaran, Ravindran
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 390 - 390
  • [26] ASSOCIATION OF IMMUNE-RELATED ADVERSE EVENTS WITH PROGNOSIS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB
    Ishihara, Hiroki
    Takagi, Toshio
    Kondo, Tsunenori
    Homma, Chie
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kobayashi, Hirohito
    Okumi, Masayoshi
    Ishida, Hideki
    Tanabe, Kazunari
    JOURNAL OF UROLOGY, 2019, 201 (04): : E71 - E71
  • [27] First-Line Immune Combination Therapies for Nonclear Cell Versus Clear Cell Metastatic Renal Cell Carcinoma: Real-World Multicenter Data From Germany
    Garcia, Cristina Cano
    Hoeh, Benedikt
    Mandal, Subhajit
    Banek, Severine
    Kluemper, Niklas
    Schmucker, Philipp
    Hahn, Oliver
    Mattigk, Angelika
    Ellinger, Joerg
    Cox, Alexander
    Becker, Philippe
    Zeuschner, Philip
    Zengerling, Friedemann
    Erdmann, Kati
    Buerk, Bjoern Thorben
    Kalogirou, Charis
    Flegar, Luka
    CLINICAL GENITOURINARY CANCER, 2024, 22 (04)
  • [28] Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center Experience
    Dizman, Nazli
    Bergerot, Paulo G.
    Bergerot, Cristiane D.
    Hsu, JoAnn
    Pal, Sumanta K.
    KIDNEY CANCER, 2019, 3 (03) : 171 - 176
  • [29] First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
    Vano, Yann-Alexandre
    Ladoire, Sylvain
    Elaidi, Reza
    Dermeche, Slimane
    Eymard, Jean-Christophe
    Falkowski, Sabrina
    Gross-Goupil, Marine
    Malouf, Gabriel
    Narciso, Berangere
    Sajous, Christophe
    Tartas, Sophie
    Voog, Eric
    Ravaud, Alain
    CANCERS, 2021, 13 (21)
  • [30] Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
    Martini, Dylan J.
    Goyal, Subir
    Liu, Yuan
    Evans, Sean T.
    Olsen, T. Anders
    Case, Katherine
    Magod, Benjamin L.
    Brown, Jacqueline T.
    Yantorni, Lauren
    Russler, Greta Anne
    Caulfield, Sarah
    Goldman, Jamie M.
    Nazha, Bassel
    Harris, Wayne B.
    Kissick, Haydn T.
    Master, Viraj A.
    Kucuk, Omer
    Carthon, Bradley C.
    Bilen, Mehmet Asim
    ONCOLOGIST, 2021, 26 (10): : E1742 - E1750
12345